CD19与CD20靶向T细胞重定向治疗后淋巴瘤的序贯抗原丢失与分支演化
本研究对7例接受CD19 CAR-T和CD20双特异性抗体序贯治疗的B细胞非霍奇金淋巴瘤患者的28份纵向标本进行分析,发现80%从CD20双特异性抗体治疗复发的患者存在CD20基因截短突变导致抗原丢失,并确认CAR-T治疗后CD19丢失及序贯CD19和CD20丢失病例,观察到分支演化与CD20表达空间异质性。
要点
- 80%从CD20双特异性抗体治疗复发的患者存在CD20基因截短突变导致抗原丢失。
- 疾病进展且保留CD20表达的病例中观察到显著T细胞耗竭。
- 确认CAR-T治疗后CD19丢失,并报告序贯CD19和CD20丢失病例。
核心结论
- 免疫治疗不仅是选择抗原丢失变异的演化瓶颈,也是这些新疗法疾病进展的复杂演化途径。
研究设计与样本
- 使用广泛分析流程对7例患者的28份纵向收集标本进行研究。
主要发现
- 80%从CD20双特异性抗体治疗复发的患者存在CD20基因截短突变导致抗原丢失。
- 疾病进展且保留CD20表达的病例中观察到显著T细胞耗竭。
- 确认CAR-T治疗后CD19丢失,并报告序贯CD19和CD20丢失病例。
- 观察到CD20+亚克隆在较晚时间点重新出现及CD20表达的空间异质性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19 chimeric antigen receptor (CAR) T cells and CD20 targeting T-cell-engaging bispecific antibodies (bispecs) have been approved in B-cell non-Hodgkin lymphoma lately, heralding a new clinical setting in which patients are treated with both approaches, sequentially. The aim of our study was to investigate the selective pressure of CD19- and CD20-directed therapy on the clonal architecture in lymphoma. Using a broad analytical pipeline on 28 longitudinally collected specimen from 7 patients, we identified truncating mutations in the gene encoding CD20 conferring antigen loss in 80% of patients relapsing from CD20 bispecs. Pronounced T-cell exhaustion was identified in cases with progressive disease and retained CD20 expression. We also confirmed CD19 loss after CAR T-cell therapy and reported the case of sequential CD19 and CD20 loss. We observed branching evolution with re-emergence of CD20+ subclones at later time points and spatial heterogeneity for CD20 expression in response to targeted therapy. Our results highlight immunotherapy as not only an evolutionary bottleneck selecting for antigen loss variants but also complex evolutionary pathways underlying disease progression from these novel therapies.
引用
- Duell J, Leipold AM, Appenzeller S, et al. Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy. Blood. 2024. PMID: 37976456. doi:10.1182/blood.2023021672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。